Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $336.94M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.73M
Average 0.81M
IRD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Opus Genetics, Inc.NASDAQ: IRD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$64.87M, compared with -$6.81M a year earlier. Trailing-twelve-month EBITDA was -$104.73M.
Context
- EBITDA amounted to 338.6% of revenue in FY2025, down 184.7 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 13 analysts of -$72.43M (-50.7%) for the fiscal year ending Dec 2026, a slowdown from the +16.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$64.87M-329.3% QoQ
- Last fiscal yearDec 2025
- -$48.07M+16.4% YoY
- LTMMar 2026
- -$104.73M-226.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -852.7% | -109.1% | +743.7 pp |
| 1 year | +16.4% | -50.7% | -67.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (48.07M) USD
- Year-over-year change
- +16.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (48.07M) | +16.4% |
| FY2024 | 2024-12-31 | (57.52M) | -477.1% |
| FY2023 | 2023-12-31 | (9.97M) | -154.7% |
| FY2022 | 2022-12-31 | 18.22M | +132.1% |
| FY2021 | 2021-12-31 | (56.69M) | — |
EBITDA vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's LTM Mar 2026 EBITDA of -$104.73M is the 8th highest of the 10 companies compared; the peer median is -$41.87M.
- Its year-over-year change of -226.0% is the lowest of 10, against a peer median of +18.9%.
- EBITDA amounts to 874.0% of revenue for IRD, versus a peer median of 530.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $127.04M | +256.7% | — | 102.6% | |
| LTM Mar 2026 | -$19.31M | +41.5% | — | — | |
| LTM Mar 2026 | -$30.19M | -68.1% | — | — | |
| LTM Mar 2026 | -$41.59M | +38.3% | — | — | |
| LTM Mar 2026 | -$41.87M | +24.2% | — | 3650.0% | |
| LTM Mar 2026 | -$64.35M | +18.9% | — | 427.9% | |
| LTM Mar 2026 | -$81.94M | +12.2% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$104.73M | -226.0% | — | 874.0% |
| LTM Mar 2026 | -$108.82M | +2.8% | — | — | |
| LTM Mar 2026 | -$116.42M | -1.3% | — | 632.1% | |
| Peer median (excluding IRD) | -$41.87M | +18.9% | — | 530.0% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 15.17M | 14.36M | 17.65M | 26.85M | 30.81M |
| Selling, General & Admin | 8.12M | 7.27M | 11.96M | 18.22M | 21.98M |
| Operating Expenses | 23.29M | 21.62M | 29.61M | 73.07M | 52.8M |
| Depreciation & Amortization | 4K | 4K | 6K | 10K | 53K |
| EBITDA | (56.69M) | 18.22M | (9.97M) | (57.52M) | (48.07M) |
| EBITDA Margin | -9624.3% | 45.7% | -52.3% | -523.3% | -338.6% |
| Operating Income | (22.71M) | 18.23M | (10.56M) | (62.07M) | (38.6M) |
| Operating Margin | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2K | 9K | 1.33M | 0 | 1.47M |
| Other Income / Expenses | (33.99M) | (23K) | 589K | 4.54M | (10.99M) |
| Income Before Tax | (56.69M) | 18.2M | (9.97M) | (57.53M) | (49.59M) |
| Pre-Tax Margin | -9625.3% | 45.7% | -52.4% | -523.4% | -349.3% |
| Income Tax Expense | 0 | 315K | 12K | 0 | 0 |
| Net Income | (56.69M) | 17.89M | (9.99M) | (57.53M) | (49.59M) |
| Net Margin | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| EPS (Basic) | (3.82) | 0.90 | (0.46) | (2.15) | (0.80) |
| EPS (Diluted) | (3.82) | 0.87 | (0.46) | (2.15) | (0.80) |
| Weighted Avg Shares | 14.85M | 19.93M | 21.59M | 26.72M | 622.22M |
| Weighted Avg Shares (Diluted) | 14.85M | 20.6M | 21.59M | 26.72M | 622.22M |
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$4.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.